APAC Breast Implants Market

APAC Breast Implants Market Size (2023 to 2028)

The APAC Breast Implants Market is predicted to grow at a CAGR of 7.10% from 2023 to 2028 and be worth USD 0.64 billion by 2028 from USD 0.46 billion in 2023.

Breast implants contain inert substances placed in/under the breast muscle. Breast implants are used for breast implants and breast reconstruction. Breast cancer is a prominent cause of death worldwide, especially in developing countries such as India and China, due to changing lifestyles, a lack of proper healthcare infrastructure, and awareness of clinical developments to treat the illness. Therefore, in Asia, breast augmentation is the most prevalent cosmetic treatment.

Factors such as rising breast cancer incidence rates in Asia and an increase in breast augmentation procedures in Asian countries are propelling the Asia Pacific breast implant market. Also, with rapid economic expansion, demand for cosmetic surgery has risen, fuelling the market growth.  However, there has been an increase in breast cosmetics treatment in Asia because of aesthetic considerations. In addition, the rising prevalence of breast cancer is another major factor driving market growth in the region's cosmetics and reconstructive surgery segments.

Technological advancements have transformed the market for breast implants. Breast implant demand is expected to rise as gummy bear breast implants become more popular and a minimally invasive under-the-muscle breast augmentation becomes available. Furthermore, high demand for highly cohesive silicone breast implants is anticipated to help market growth. Moreover, increasing disposable income per capita in Asian countries is augmenting the cosmetic surgery segment in APAC.  The increased demand for breast implants among Asian women is primarily attributable to their socioeconomic status. Women from middle and upper-income households are the most likely candidates for breast implant surgery.

In Addition, the market growth is expected to be fuelled by rising medical tourism in Asian nations, improving healthcare facilities, and supportive government policies. On the other hand, the rising prevalence of breast cancer in the Asia Pacific area is expected to drive demand for breast implants. As a result, the breast implant market is projected to expand strongly in emerging regional markets such as China and India.

However, the market is expected to negatively affect the risks associated with breast implants, such as breast pain and infection. In Addition, the high cost of breast augmentation is also expected to hinder the market's expansion.

This research report on the APAC breast implants market has been segmented and sub-segmented into the following categories:

By Product:

• Silicone Breast Implants
• Saline Breast Implants

By Shape:

• Round
• Anatomical

By Application:

• Reconstructive Surgery
• Cosmetic Surgery

By End-Use:

• Hospitals
• Cosmetology Clinics
• Ambulatory Surgical Centers

By Country:

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand, Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

The APAC Breast implants market is anticipated to account for a significant share during the forecast period. The market growth is expected to be fuelled by rising medical tourism in Asian nations, improving healthcare facilities, and supportive government policies. On the other hand, the rising prevalence of breast cancer in Asia is expected to drive up demand for breast implants. The breast implant market is projected to expand strongly in emerging regional markets such as China and India.

In the Asia Pacific region, breast cancer is a significant health concern. According to Cancer Australia, 19,807 new female breast cancer cases will be diagnosed in 2020. It further stated that in 2020, there would be an anticipated 2,997 female fatalities in Australia owing to breast cancer. In Australia, it is the second most diagnosed cancer.

Regarding value, China dominated the Asia Pacific breast implant market with a significant share. Factors such as heredity, confident lifestyle choices, obesity and overweight, and increased alcohol intake contribute to the rise in breast cancer cases. Similarly, the risk of breast cancer in China is rising. According to the Globocan 2018 report, China saw 367,900 new breast cancer cases in 2018. Breast cancer is the most frequent cancer among Indian women as well. According to the Globocan 2018 data, India saw 162,468 new instances of breast cancer and 87090 fatalities from the disease. In Addition, because of the rising prevalence of breast cancer and associated risk factors in China, breast implants are expected to become more prevalent in the coming years.

KEY MARKET PLAYERS:

AbbVie Inc. (Allergan plc), Establishment Labs SA, GC Aesthetics, Groupe Sebbin SAS, Laboratories Arion, Johnson & Johnson (Mentor Worldwide LLC), Polytech Health & Aesthetics GmbH, Silimed, Sientra Inc., and Celaplas are some of the noteworthy companies in the APAC breast implants market.